The recipients of this year's Richard C. Talamo Distinguished Clinical Achievement Award, presented at the 2014 North American Cystic Fibrosis Conference, represent a successful collaboration between researchers and clinicians to bring about a significant advance in CF care and treatment. The award is one of the highest honors given by the Cystic Fibrosis Foundation.
Site Search
Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.
William Skach, MD, Chief Scientific Officer, will retire from the CF Foundation this summer.
The Cystic Fibrosis Foundation awarded Talee Bio Inc. up to $4.5 million to develop methods for delivering potential gene therapy treatments to the lungs.
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
Yesterday, the Cystic Fibrosis Foundation met with HHS Secretary Tom Price and seven other patient advocacy groups to discuss drug pricing and the needs of the CF community. President Trump has identified drug pricing as a top priority, and this meeting was the start of a listening tour by the Secretary.
The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation's commitment to advance innovative solutions to the growing challenge of antibiotic resistance.